Nine major PBMs agree to display TrumpRx cash prices for patients
Nine leading pharmacy benefit managers, including CVS, Express Scripts, and Optum Rx, announced Thursday they will display TrumpRx cash prices alongside plan benefit prices in their real-time benefit tools and other pricing platforms. The agreement, coordinated with the Trump administration and CMS Administrator Dr. Mehmet Oz, covers Medicare, Medicaid, and commercial plans. TrumpRx is a government-run platform launched in February that helps patients compare direct-to-consumer prescription drug cash prices. The PBMs say the move increases transparency so patients can see both their insured costs and cash price alternatives. Administration officials describe it as fostering competition and helping patients find the best deals. The announcement follows months of pressure on PBMs through new legislation, proposed regulations requiring greater disclosure, and prior FTC enforcement action against Express Scripts over rebate practices. Supporters say the transparency move respects patient choice, while critics worry TrumpRx focuses only on cash payments and doesn't address underlying PBM control over coverage decisions.
Key facts
- Nine PBMs—CVS Caremark, Optum Rx, Express Scripts, CarelonRx, Humana, MedImpact, Navitus, Prime Therapeutics, WellDyne, and VytlOne—agreed on August 13, 2026 to display TrumpRx prices in their benefit tools
- The agreement covers Medicare, Medicaid, and commercial insurance plans
- TrumpRx was launched February 5, 2026 with roughly 40 brand-name drugs and expanded to over 600 generic medications by May 2026
- In March 2026, KFF polling found only 7 percent of regular prescription drug users had visited TrumpRx to compare prices
- In February 2026, the FTC settled with Express Scripts over rebate practices that contributed to inflated insulin prices and higher patient costs
- Congress passed PBM reforms in the Consolidated Appropriations Act 2026 that delink PBM compensation from drug list prices and require flat administrative fees
How different outlets framed it
Left-leaning coverage: Critics highlight that TrumpRx transparency alone doesn't solve affordability because most Americans still rely on employer insurance where PBMs control coverage approval and distribution. They argue the platform benefits those who can afford out-of-pocket payments and that many drugs remain unaffordable even at TrumpRx prices, with some like GLP-1 medications still costing 200 to 300 dollars monthly. Deeper reform would require dismantling the opaque rebate structures and systemic incentives that give PBMs gatekeeping power.
Right-leaning coverage: Right-leaning sources present the PBM agreement as evidence of the Trump administration successfully lowering drug costs through market-based solutions, deregulation, and voluntary private-sector commitment. They highlight that the administration's direct negotiation approach and transparency initiatives encourage competition and empower patients with information. The narrative emphasizes success in pressuring industry players to commit to reforms without heavy-handed mandates.
Limits of this briefing
Most Americans still obtain medications through employer insurance plans where PBMs control coverage decisions, not just pricing display. The long-term impact depends on actual patient awareness and usage of TrumpRx, which remains low, and whether the transparency translates into real savings reaching consumers.
Sources
- Fox Business: Nine major PBMs agree to display TrumpRx drug prices on benefit tools Right
- Fierce Healthcare: Major PBMs agree to offer TrumpRx pricing information to members Centre
- US News & World Report Opinion: Prescription Drug Prices Are a Problem – But TrumpRx Is Not the Solution Left
- STAT News: PBMs warn Trump's proposal to disclose drug prices is illegal Centre
- AJMC (American Journal of Managed Care): PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency Centre